KNOPP BIOSCIENCES

Knopp Biosciences LLC is a privately held company managing a portfolio of equity securities and future product royalties. Founded in 2004, the company enjoyed an 18 year record of drug discovery in challenging immunological and neurological diseases. Knopp's clinical-stage oral small molecule, dexpramipexole, is currently being developed for eosinophilic asthma by Areteia Therapeutics, Inc. (www.areteiatx.com), a portfolio company of Bain Capital Life Sciences.

Also known as: Knopp Biosciences LLC